Background: Mesenchymal stem cells (MSC) are easily harvested, and possess anti-inflammatory and trophic properties. Furthermore, MSC promote neuroprotection and neurogenesis, which could greatly benefit neurodegenerative disorders, such as Parkinson's disease. Methods: MSC were transplanted one week after 6-hydroxydopamine lesioning and effects were evaluated after 6 months. Results: MSC localized around the substantia nigra and the arachnoid mater, expressing pericyte and endothelial markers. MSC protected dopamine levels and upregulated peripheral anti-inflammatory cytokines. Furthermore, adipose-derived MSC increased neurogenesis in hippocampal and subventricular regions, and boosted memory functioning. Conclusion: Considering that hyposmia and loss of memory function are two major nonmotor symptoms in Parkinson's disease, transplants with modulatory effects on the hippocampus and subventricular zone could provide a disease-modifying therapy.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Schapira AH. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol. Sci. 30(1), 41–47 (2009).
Medline CASGoogle Scholar
2 Braak H, Del Tredici K, Rub U, De Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24(2), 197–211 (2003).
MedlineGoogle Scholar
3 Ubeda-Banon I, Saiz-Sanchez D, De La Rosa-Prieto C et al. alpha-Synucleinopathy in the human olfactory system in Parkinson's disease: involvement of calcium-binding protein- and substance P-positive cells. Acta Neuropathol. 119(6), 723–735 (2010).
Medline CASGoogle Scholar
4 Hoglinger GU, Rizk P, Muriel MP et al. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat. Neurosci. 7(7), 726–735 (2004).•• Essential study on neurogenesis, showing that precursor proliferation in the adult subependymal and subgranular zone depends on dopaminergic ennervation and is consequently reduced upon dopaminergic dennervation.
MedlineGoogle Scholar
5 Pearce RK, Hawkes CH, Daniel SE. The anterior olfactory nucleus in Parkinson's disease. Mov. Disord. 10(3), 283–287 (1995).
Medline CASGoogle Scholar
6 Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60(3), 387–392 (2003).
MedlineGoogle Scholar
7 Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA. Parkinson's disease is associated with hippocampal atrophy. Mov. Disord. 18(7), 784–790 (2003).
MedlineGoogle Scholar
8 Doty RL. Olfactory dysfunction in Parkinson disease. Nat. Rev. Neurol. 8(6), 329–339 (2012).
Medline CASGoogle Scholar
9 Lesemann A, Reinel C, Huhnchen P et al. MPTP-induced hippocampal effects on serotonin, dopamine, neurotrophins, adult neurogenesis and depression-like behavior are partially influenced by fluoxetine in adult mice. Brain Res. 1457, 51–69 (2012).
Medline CASGoogle Scholar
10 Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 37(3), 510–518 (2010).
Medline CASGoogle Scholar
11 Yasuhara T, Shingo T, Muraoka K et al. Neurorescue effects of VEGF on a rat model of Parkinson's disease. Brain Res. 1053(1–2), 10–18 (2005).
Medline CASGoogle Scholar
12 Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridge WM. Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse. Brain Res. 1382, 315–320 (2011).
Medline CASGoogle Scholar
13 Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y. Immunobiology of mesenchymal stem cells. Cell Death Different. 21(2), 216–225 (2013).
MedlineGoogle Scholar
14 Boomsma RA, Geenen DL. Mesenchymal Stem Cells Secrete Multiple Cytokines That Promote Angiogenesis and Have Contrasting Effects on Chemotaxis and Apoptosis. PLoS ONE 7(4), e35685 (2012).
Medline CASGoogle Scholar
15 Kilroy GE, Foster SJ, Wu X et al. Cytokine profile of human adipose-derived stem cells: expression of angiogenic, hematopoietic, and pro-inflammatory factors. J. Cell. Physiol. 212(3), 702–709 (2007).
Medline CASGoogle Scholar
16 Abumaree M, Al Jumah M, Pace RA, Kalionis B. Immunosuppressive properties of mesenchymal stem cells. Stem Cell Rev. 8(2), 375–392 (2012).
Medline CASGoogle Scholar
17 Devine SM, Bartholomew AM, Mahmud N et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp. Hematol. 29(2), 244–255 (2001).
Medline CASGoogle Scholar
18 Mogi M, Togari A, Kondo T et al. Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains. Neurosci. Lett. 300(3), 179–181 (2001).
Medline CASGoogle Scholar
19 Mogi M, Togari A, Kondo T et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett. 270(1), 45–48 (1999).
Medline CASGoogle Scholar
20 Cova L, Armentero MT, Zennaro E et al. Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease. Brain Res. 1311, 12–27 (2010).
Medline CASGoogle Scholar
21 Park HJ, Shin JY, Lee BR, Kim HO, Lee PH. Mesenchymal stem cells augment neurogenesis in the subventricular zone and enhance differentiation of neural precursor cells into dopaminergic neurons in the substantia nigra of a parkinsonian model. Cell Transplant. 21(8), 1629–1640 (2012).
MedlineGoogle Scholar
22 Coquery N, Blesch A, Stroh A et al. Intrahippocampal transplantation of mesenchymal stromal cells promotes neuroplasticity. Cytotherapy 14(9), 1041–1053 (2012).
Medline CASGoogle Scholar
23 Izadpanah R, Trygg C, Patel B et al. Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J. Cell. Biochem. 99(5), 1285–1297 (2006).
Medline CASGoogle Scholar
24 Vidal MA, Walker NJ, Napoli E, Borjesson DL. Evaluation of senescence in mesenchymal stem cells isolated from equine bone marrow, adipose tissue, and umbilical cord tissue. Stem Cells Dev. 21(2), 273–283 (2012).
MedlineGoogle Scholar
25 Zhang HT, Liu ZL, Yao XQ, Yang ZJ, Xu RX. Neural differentiation ability of mesenchymal stromal cells from bone marrow and adipose tissue: a comparative study. Cytotherapy 14(10), 1203–1214 (2012).
Medline CASGoogle Scholar
26 Mccoy MK, Martinez TN, Ruhn KA et al. Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of Parkinson's disease. Exp. Neurol. 210(1), 14–29 (2008).
Medline CASGoogle Scholar
27 Berg J, Roch M, Altschuler J et al. Human adipose-Derived Mesenchymal Stem Cells Improve Motor Functions and are Neuroprotective in the 6-Hydroxydopamine-Rat Model for Parkinson's Disease when Cultured in Monolayer Cultures but Suppress Hippocampal Neurogenesis and Hippocampal Memory Function when Cultured in Spheroids. Stem Cell Rev. 11(1), 133–149 (2014).•• Goundwork study for our study, which showed neuroprotective and effects of adipose-derived mesenchymal stem cells in a Parkinson's disease rat model.
Google Scholar
28 Ahmed H, Salem A, Atta H, Ghazy M, Aglan H. Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson's disease in rat model? Hum. Exp. Toxicol. 33(12), 1217–1231 (2014).
Medline CASGoogle Scholar
29 Schwerk A, Altschüler J, Roch M et al. Human adipose-derived mesenchymal stromal cells increase endogenous neurogenesis in the rat subventricular zone acutely after 6-hydroxydopamine lesioning. Cytotherapy 17(2), 199–214 (2015).
Medline CASGoogle Scholar
30 Frangioni JV, Hajjar RJ. In vivo tracking of stem cells for clinical trials in cardiovascular disease. Circulation 110(21), 3378–3383 (2004).
MedlineGoogle Scholar
31 Glavaski-Joksimovic A, Virag T, Chang QA et al. Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors. Cell Transpl. 18(7), 801–814 (2009).
MedlineGoogle Scholar
32 Park HJ, Lee PH, Bang OY, Lee G, Ahn YH. Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. J. Neurochem. 107(1), 141–151 (2008).• Important study, which showed neuroprotective effects and a dopaminergic transdifferentiation of mesenchymal stem cells in a Parkinson's disease rat model.
Medline CASGoogle Scholar
33 Wang W, Itaka K, Ohba S et al. 3D spheroid culture system on micropatterned substrates for improved differentiation efficiency of multipotent mesenchymal stem cells. Biomaterials 30(14), 2705–2715 (2009).
Medline CASGoogle Scholar
34 Weiss ML, Medicetty S, Bledsoe AR et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells 24(3), 781–792 (2006).
Medline CASGoogle Scholar
35 Yuan H, Sarre S, Ebinger G, Michotte Y. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J. Neurosci. Methods 144(1), 35–45 (2005).
MedlineGoogle Scholar
36 Blandini F, Cova L, Armentero MT et al. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant. 19(2), 203–217 (2010).
MedlineGoogle Scholar
37 Danielyan L, Schafer R, Von Ameln-Mayerhofer A et al. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res. 14(1), 3–16 (2011).
Medline CASGoogle Scholar
38 Tepper JM, Damlama M, Trent F. Postnatal changes in the distribution and morphology of rat substantia nigra dopaminergic neurons. Neuroscience 60(2), 469–477 (1994).
Medline CASGoogle Scholar
39 Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates (5th Edition). Elsevier Academic Pres, Amsterdam, The Netherlands (2005).
Google Scholar
40 Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24(3), 485–493 (1970).
Medline CASGoogle Scholar
41 Balschun D, Manahan-Vaughan D, Wagner T, Behnisch T, Reymann KG, Wetzel W. A specific role for group I mGluRs in hippocampal LTP and hippocampus-dependent spatial learning. Learn. Mem. 6(2), 138–152 (1999).
Medline CASGoogle Scholar
42 Decimo I, Fumagalli G, Berton V, Krampera M, Bifari F. Meninges. from protective membrane to stem cell niche. Am. J. Stem Cells 1(2), 92–105 (2012).
Medline CASGoogle Scholar
43 Nakagomi T, Molnar Z, Taguchi A et al. Leptomeningeal-derived doublecortin-expressing cells in poststroke brain. Stem Cells Dev. 21(13), 2350–2354 (2012).
Medline CASGoogle Scholar
44 Popescu BO, Gherghiceanu M, Kostin S, Ceafalan L, Popescu LM. Telocytes in meninges and choroid plexus. Neurosci. Lett. 516(2), 265–269 (2012).
Medline CASGoogle Scholar
45 Mercier F, Hatton GI. Connexin 26 and basic fibroblast growth factor are expressed primarily in the subpial and subependymal layers in adult brain parenchyma. roles in stem cell proliferation and morphological plasticity? J. Compar. Neurol. 431(1), 88–104 (2001).
Medline CASGoogle Scholar
46 Stylianopoulou F, Herbert J, Soares MB, Efstratiadis A. Expression of the insulin-like growth factor II gene in the choroid plexus and the leptomeninges of the adult rat central nervous system. Proc. Natl Acad. Sci. USA 85(1), 141–145 (1988).
Medline CASGoogle Scholar
47 Steiner B, Kronenberg G, Jessberger S, Brandt MD, Reuter K, Kempermann G. Differential regulation of gliogenesis in the context of adult hippocampal neurogenesis in mice. Glia 46(1), 41–52 (2004).•• Key paper on neurogenesis, which assessed the amount of neuronal precursors in proliferating cells of the dentate gyrus.
MedlineGoogle Scholar
48 Campos FL, Carvalho MM, Cristovao AC et al. Rodent models of Parkinson's disease: beyond the motor symptomatology. Front. Behav. Neurosci. 7, 175 (2013).
MedlineGoogle Scholar
49 Domellof ME, Elgh E, Forsgren L. The relation between cognition and motor dysfunction in drug-naive newly diagnosed patients with Parkinson's disease. Mov. Disord. 26(12), 2183–2189 (2011).
MedlineGoogle Scholar
50 Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov. Disord. 21(9), 1343–1349 (2006).
MedlineGoogle Scholar
51 Johnston LC, Su X, Maguire-Zeiss K et al. Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. Mol. Ther. 16(8), 1392–1399 (2008).
Medline CASGoogle Scholar
52 Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15(1), 120–132 (2002).
Medline CASGoogle Scholar
53 Meredith GE, Kang UJ. Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov. Disord. 21(10), 1595–1606 (2006).
MedlineGoogle Scholar
54 Chang JW, Wachtel SR, Young D, Kang UJ. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88(2), 617–628 (1999).
Medline CASGoogle Scholar
55 Sakanaka M, Wen TC, Matsuda S et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl Acad. Sci. USA 95(8), 4635–4640 (1998).
Medline CASGoogle Scholar
56 Wang L, Zhang ZG, Zhang RL et al. Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J. Neurosci. 26(22), 5996–6003 (2006).
Medline CASGoogle Scholar
57 Kiyota T, Ingraham KL, Swan RJ, Jacobsen MT, Andrews SJ, Ikezu T. AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. Gene Ther. 19(7), 724–733 (2012).
Medline CASGoogle Scholar
58 Perez-Asensio FJ, Perpina U, Planas AM, Pozas E. Interleukin-10 regulates progenitor differentiation and modulates neurogenesis in adult brain. J. Cell Sci. 126(Pt 18), 4208–4219 (2013).
Medline CASGoogle Scholar
59 Acquistapace A, Bru T, Lesault PF et al. Human mesenchymal stem cells reprogram adult cardiomyocytes toward a progenitor-like state through partial cell fusion and mitochondria transfer. Stem Cells 29(5), 812–824 (2011).
Medline CASGoogle Scholar
60 Nygren JM, Jovinge S, Breitbach M et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat. Med. 10(5), 494–501 (2004).
Medline CASGoogle Scholar
61 Paredes MF, Li G, Berger O, Baraban SC, Pleasure SJ. Stromal-derived factor-1 (CXCL12) regulates laminar position of Cajal-Retzius cells in normal and dysplastic brains. J. Neurosci. 26(37), 9404–9412 (2006).
Medline CASGoogle Scholar
62 Decimo I, Bifari F, Rodriguez FJ et al. Nestin- and doublecortin-positive cells reside in adult spinal cord meninges and participate in injury-induced parenchymal reaction. Stem Cells 29(12), 2062–2076 (2011).• Essential study on neurogenesis showing that precursor proliferation in the adult subependymal and subgranular zone depends on dopaminergic ennervation and is consequently reduced upon dopaminergic dennervation.
Medline CASGoogle Scholar
63 Nakagomi T, Molnar Z, Nakano-Doi A et al. Ischemia-induced neural stem/progenitor cells in the pia mater following cortical infarction. Stem Cells Dev. 20(12), 2037–2051 (2011).
Medline CASGoogle Scholar
64 Decimo I, Bifari F, Krampera M, Fumagalli G. Neural stem cell niches in health and diseases. Curr. Pharm. Des. 18(13), 1755–1783 (2012).
Medline CASGoogle Scholar
65 Bestor TH. Gene silencing as a threat to the success of gene therapy. J. Clin. Invest. 105(4), 409–411 (2000).
Medline CASGoogle Scholar
66 Ellis J, Yao S. Retrovirus silencing and vector design: relevance to normal and cancer stem cells? Curr. Gene Ther. 5(4), 367–373 (2005).
Medline CASGoogle Scholar
67 Pannell D, Ellis J. Silencing of gene expression: implications for design of retrovirus vectors. Rev. Med. Virol. 11(4), 205–217 (2001).
Medline CASGoogle Scholar
68 Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 3(4), 393–403 (1970).
Medline CASGoogle Scholar
69 Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4(3), 206–216 (2009).
Medline CASGoogle Scholar
70 Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol. 503, 269–292 (2012).
Medline CASGoogle Scholar
71 Nerem RM. Cell-based therapies: from basic biology to replacement, repair, and regeneration. Biomaterials 28(34), 5074–5077 (2007).
Medline CASGoogle Scholar
72 Ikegame Y, Yamashita K, Hayashi S et al. Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy. Cytotherapy 13(6), 675–685 (2011).
Medline CASGoogle Scholar
73 Mizuno H, Hyakusoku H. Mesengenic potential and future clinical perspective of human processed lipoaspirate cells. J. Nippon Med. Sch. 70(4), 300–306 (2003).
MedlineGoogle Scholar
74 Niemeyer P, Kornacker M, Mehlhorn A et al. Comparison of immunological properties of bone marrow stromal cells and adipose tissue-derived stem cells before and after osteogenic differentiation in vitro. Tissue Eng. 13(1), 111–121 (2007).
Medline CASGoogle Scholar

Vol. 10, No. 4

Supplemental Materials

Metrics

Downloaded 422 times

History

Published online 29 May 2015

Published in print May 2015

Information

Keywords

Acknowledgements

Special thanks to M Hofstätter for her kind help with the construction of the GFP-vector.

Financial & competing interests disclosure

This study was funded by the ERFE grant of the Investitionsbank Berlin to B Steiner. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download